Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001-2010.
Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy.
Rituximab: Don't Count It Out as MS Treatment
Altered microRNA expression in B lymphocytes in multiple sclerosis: Towards a better understanding of treatment effects.
Higher Relative Risk for Multiple Sclerosis in a Pediatric and Adolescent Diabetes Population: Analysis From DPV Data Base.
Expression and activation by epstein barr virus of human endogenous retroviruses-w in blood cells and astrocytes: inference for multiple sclerosis.
Effect of Genzyme’s LEMTRADA™ maintained in patients beyond two-year pivotal MS studies
Idiopathic aquaporin-4 antibody negative longitudinally extensive transverse myelitis.
Mapi Pharma Receives Additional Claims for Its U.S. Patent for Glatiramer Acetate Depot for the Treatment of Multiple Sclerosis
RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherence.
Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod.
Narcolepsy with cataplexy and comorbid immunopathological diseases.
Laquinimod - New Promising Treatment for Multiple Sclerosis
New data show positive results from Phase 4 study of Avonex Pen for treatment of RRMS patients
Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.
Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results.
Interference with RhoA-ROCK Signaling Mechanism in Autoreactive CD4(+) T Cells Enhances the Bioavailability of 1,25-Dihydroxyvitamin D(3) in Experimental Autoimmune Encephalomyelitis.
Glatiramer acetate treatment effects on gene expression in monocytes of multiple sclerosis patients.
First NW patient to receive OHSU/VAMC-invented MS drug
Ceramide Synthase 6 Plays a Critical Role in the Development of Experimental Autoimmune Encephalomyelitis.
Targeted ablation of oligodendrocytes induces axonal pathology independent of overt demyelination.
A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica).
Arzerra receives approval in Japan
Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity.
Conformational Landscape of N-Glycosylated Peptides Detecting Autoantibodies in Multiple Sclerosis, Revealed by Hamiltonian Replica Exchange.

Pages